in the information, the patient was contacted or seen again in the clinic to obtain the missing data.
contractions of orbicularis oculi, is now believed to be a neurological disease. As a result of increased publicity and general awareness of this disabling condition, more and more patients are being recognised throughout the world. Prevalence data are limited, but a survey of the Mayo Clinic register estimated a figure of about 5 per 100,000 (Nutt, unpublished observations). There may therefore be some 3,000 affected individuals in the United Kingdom. To assist neurologists and ophthalmologists in advising patients with blepharospasm on the possible precipitants and inheritance of their illness, its natural history and chances of remission, and the outcome of the various treatment options for this condition, we present here a review of 264 patients seen at Moorfields Eye Hospital and the Maudsley Hospital.
Patients and results
The case notes of the 264 patients were reviewed to obtain answers to a standard questionnaire. Where there were gaps tPresent address: Departimento Neurologia, Clinica Universitaria, Apartado 192, Pamplona, Spain. in the information, the patient was contacted or seen again in the clinic to obtain the missing data.
The mean age of onset was 55 8 (SD 12 5) years (range 11-81). There were 170 females (644%) and 94 males (35-6%) . The female/male ratio was 1-8:1.
Antecedent events
There was a psychiatric illness before or at onset of blepharospasm in 47 cases (17-8%) . Twenty nine patients (11%) were depressed; two had a bipolar manic-depressive illness; 10 (3 8%) suffered an anxiety state; four were schizophrenic; two had a single unspecified psychotic episode. Fourteen of these cases (5-3% of the total series) were exposed to neuroleptics before the onset of their blepharospasm, so may have been examples of tardive dystonia. Thus, only 33 patients (13-2%) with non-tardive blepharospasm had a prior history of psychiatric disorder.
Thirty two cases (12-1 %) had experienced local ocular disease in the year before the onset of their blepharospasm. In addition, a larger number of patients (55-3%) complained of ocular symptoms prior to or at the onset of their blepharospasm (table 1) (2 3%) , and increased blinking in nine cases (3.4%). Dystonia other than blepharospasm occurred in other family members in 10 cases (3-8%). If increased blinking is considered an early manifestation of blepharospasm, a total of 25 patients (9 5%) had a family history of dystonia. Other conditions reported in the family of some patients were Parkinson's disease (11 cases) and essential tremor (9 cases), which is not more than expected by chance. In addition, two patients had a family history of tics, and one each of Huntington's chorea, Sydenham's chorea and orofacial dyskinesia.
Clinical features
The onset was unilateral in 52 cases (19 7% ) but the blepharospasm became bilateral in all but four patients. The mean interval between the onset of unilateral blepharospasm and the spread to the other eye was 2 (SD 5 8) years. Ninety eight cases (37 1%) experienced excessive blinking before typical spasms occurred. The mean interval from the onset of blinking to the appearance of spasms was 7 9 (SD 14-5) years.
The intensity and frequency of spasms were increased by bright lights in 50 7%, watching television in 47-7%, reading in 35 6%, stress in 42% and driving in 28 4%. Blepharospasm improved after sleep in 32 8%, relaxation in 29 2%, concentration in 25 7%, looking down in 7-2%, and movements involving the oro-facial area such as talking, yawning, singing, and grimacing in 25 4%. Many patients (17%) had special "tricks" in order to open the eyes, such as touching or pulling the eyelids slightly; these may be regarded as the equivalent the "geste antagoniste" seen in other forms of dystonia.
Many patients were severely disabled by their blepharospasm before treatment. Approximately two-thirds of patients were rendered functionally blind to the extent that they were judged to require surgery or botulinum toxin injections to restore vision. Many had to give up work, or could not leave the house alone because they were "blind".
Grandas, Elston, Quinn, Marsden After treatment with botulinum toxin injections, 49 patients (32-4%) remarked on improvement of their lower facial and/or oromandibular dystonia.
Side effects are described in Table 6 . Sixty-seven patients (44-3%) had transient (1-35 days) unilateral or bilateral ptosis. Seventeen cases (11-3%) had transient (1-45 days) diplopia. Seven cases (4 6%) had significant but transient (1-10 days) lower facial weakness.
Persistent disabling problems emerged after botulinum toxin injections in 23 cases (15-2%). Fifteen patients (9 9%) had a persistent spontaneous Bell's phenomenon, six (3-9%) experienced persistent levator inhibition, and two (1-3%) had levator disinsertion. These problems prevented complete restoration of useful vision. Levator Grandas, Elston, Quinn, Marsden glia or upper brainstem, the most reasonable hypothesis is that dysfunction of descending basal ganglia pathways causes hyperexcitability of the brainstem interneurons responsible for the blink reflex.
However, this abnormality of the blink reflex has also been found in some patients with lower cranial dystonia and even torticollis, but without blepharospasm;28 we have confirmed this observation (unpublished observations). This suggests that something else is required to trigger frank blepharospasm in those predisposed to this condition.
One clue to such a trigger is the high incidence of local ocular symptoms and signs prior to or at the onset of blepharospasm. In our series, 56-8% of patients reported local ocular symptoms (photophobia, dry eyes, soreness, ocular pain or watering eyes) prior to or at the onset of their blepharospasm, and 12-1% had signs of local eye disease. It is most unlikely that these ocular symptoms and signs were due to the blepharospasm, for only 4-9% of the patients developed such problems later in the course of the established disease. The suggestion is that in many cases local eye disease may trigger blepharospasm in those so predisposed. A similar role for local trauma precipitating a focal dystonia in some cases also has been suggested for spasmodic torticollis,29 writer's cramp30 and other dystonias. 31 32 In a past era, blepharospasm was often attributed to psychiatric illness or psychological disorders. However, only a minority of patients have overt psychiatric illness prior to the onset of their blepharospasm; excluding those with neuroleptic induced blepharospasm, only 13-2% of cases in this series had a psychiatric illness prior to or at the onset of their blepharospam. This is not likely to be of significance.
Turning to treatment, only about one in five of our patients gained benefit from drug therapy. Many drugs have been claimed to relieve blepharospasm,33 39 but there is no consistent pharmacological response.40 -42 Anticholinergic drugs probably give the best chance of benefit,43 -46 but side effects are common and the response is inconsistent. The chances of drugs helping are confounded by the problem of spontaneous remissions of the condition. Such remissions, which were temporary in most patients, were reported in 11-4% of our cases. It is difficult to decide whether improvement of blepharospasm on drug therapy is due to the pharmacological effects of the drug, a placebo response, a spontaneous remission or a drug-induced remission. Controlled trials are necessary to resolve these questions, but few have been undertaken in blepharospasm.
Different surgical approaches were tried to relieve blepharospasm. Bilateral avulsion of facial nerves47 48 was the most successful, producing initial improvement in more than 90% of the patients. Injection of botulinum toxin type A into orbicularis oculi has recently been introduced for the treatment of blepharospasm.52-59 Botulinum neurotoxin binds to peripheral motor nerve terminals and inhibits the release of acetylcholine.606' Botulinum toxin injections produced a significant improvement in more than 75% of the treated patients, with almost complete disappearance of blepharospasm in one third. The benefit is maintained on average between 9 and 10 weeks, which implies that injections should be repeated about five times a year, however occasional patients benefit for considerably longer periods.
Side effects are common but usually local and transient. Nevertheless botulinum toxin injections is so far the best therapeutic measure that can be offered to patients with disabling blepharospasm.
